Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin01:26

Directly Acting Muscle Relaxants: Dantrolene and Botulinum Toxin

780
Directly acting muscle relaxants like dantrolene and botulinum toxin (BoNT) have distinct mechanisms and applications. Dantrolene, a hydantoin derivative, acts on the ryanodine receptor (RYR1) in skeletal muscle cells. RYR1 are calcium channels present at the sarcoplasmic reticulum membrane. In response to excitation, they release calcium ions from the sarcoplasmic reticulum to the cytosol. Calcium promotes actin-myosin-mediated contraction of muscles.
The binding of dantrolene to the RYR1...
780
Skeletal Muscle Relaxants: Therapeutic Uses01:31

Skeletal Muscle Relaxants: Therapeutic Uses

634
Skeletal muscle relaxants are used to relax muscle tone and alleviate painful muscle contractions. However, the choice of skeletal muscle relaxants depends on the duration of the surgical procedure in order to minimize potential side effects. Skeletal muscle relaxants like neuromuscular blocking agents [NMBAs] are commonly employed as adjuvants alongside general anesthetics in clinical settings. NMBAs are also used to maintain controlled ventilation during surgery of the larynx or pharynx...
634
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

389
Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
389
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

1.9K
Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because...
1.9K
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

2.0K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Interstitial granulomatous dermatitis presenting with the rope sign in a patient with systemic lupus erythematosus.

JAAD case reports·2026
Same author

Neutrophilic Eccrine Hidradenitis in a Patient With Intranasal Cocaine Use.

The Australasian journal of dermatology·2026
Same author

Rural, Regional, Remote Residence, Anxiolytic Use, Multiple Site Surgery, Smoking Status Associated With Patient-Initiated Communication After Mohs Micrographic Surgery.

The Australasian journal of dermatology·2026
Same author

Familial prevalence of psoriasis in patients with multiple sclerosis - results from an Australian survey.

Frontiers in neurology·2025
Same author

Treatment of Hallux Rigidus: Comparison of Hemiarthroplasty with Cartiva Implant, Allograft Interpositional Arthroplasty, and Arthrodesis.

Foot & ankle orthopaedics·2025
Same author

Evaluating the accuracy of extrapolated overall survival for pembrolizumab: a comparison with long-term observed data in the Australian reimbursement context.

Expert review of pharmacoeconomics & outcomes research·2025
Same journal

Awareness level regarding adverse reactions caused by cosmetic products among indian women: A cross-sectional study.

Journal of cutaneous and aesthetic surgery·2025
Same journal

Should high BMI of transmasculine patients prevent them from masculinizing their chest walls?

Journal of cutaneous and aesthetic surgery·2025
Same journal

Intralesional immunotherapy of cutaneous warts using tuberculin purified protein derivative and vitamin D<sub>3</sub> - A randomized comparative study.

Journal of cutaneous and aesthetic surgery·2025
Same journal

Effectiveness of intralesional bleomycin in the management of difficult-to-treat and resistant cutaneous warts in a tertiary care teaching hospital in Puducherry: A quasi-experimental study.

Journal of cutaneous and aesthetic surgery·2025
Same journal

Platelet-rich fibrin therapy as an adjuvant treatment in the management of metastatic Crohn's disease: A case series.

Journal of cutaneous and aesthetic surgery·2025
Same journal

Bicalutamide: A review.

Journal of cutaneous and aesthetic surgery·2025
See all related articles

Related Experiment Video

Updated: Sep 21, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.4K

Botulinum Toxin for Scalp Dysesthesia.

Kevin Phan1, Matthew James Lin2

  • 1St George Dermatology and Skin Cancer Centre, Kogarah, Australia.

Journal of Cutaneous and Aesthetic Surgery
|June 3, 2022
PubMed
Summary
This summary is machine-generated.

Botulinum toxin may help manage scalp dysesthesia, a condition causing burning and itching sensations. This study explores its unique use in treating this challenging neuropathic pain condition.

Keywords:
Botoxbotulinum toxininjectablesintralesionalscalp dysesthesia

More Related Videos

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
06:13

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain

Published on: March 1, 2024

1.1K
Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

19.0K

Related Experiment Videos

Last Updated: Sep 21, 2025

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea
07:05

Ultrasound-guided Botulinum Toxin-A Injections: A Method of Treating Sialorrhea

Published on: November 9, 2016

23.4K
Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain
06:13

Author Spotlight: Insights into Remotely Supervised Neuromodulation Procedure for Phantom Limb Pain

Published on: March 1, 2024

1.1K
Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain
09:35

Subcutaneous Trigeminal Nerve Field Stimulation for Refractory Facial Pain

Published on: May 10, 2017

19.0K

Area of Science:

  • Neurology
  • Dermatology

Background:

  • Scalp dysesthesia involves abnormal sensations like burning, stinging, or itching.
  • Effective treatments for scalp dysesthesia are limited, posing a management challenge.

Observation:

  • Botulinum toxin is known to inhibit neurotransmitter release, including substance P, glutamate, and calcitonin gene-related peptide.
  • These neurotransmitters are implicated in neuropathic pain pathways.

Findings:

  • This report details a unique case utilizing botulinum toxin for scalp dysesthesia management.
  • Botulinum toxin demonstrated potential in alleviating symptoms associated with scalp dysesthesia.

Implications:

  • Botulinum toxin may offer a novel therapeutic option for recalcitrant scalp dysesthesia.
  • Further research into botulinum toxin's efficacy for neuropathic scalp conditions is warranted.